A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy.

Published

Journal Article

OBJECTIVE:Many previous studies of drug repurposing have relied on literature review followed by evaluation of a limited number of candidate compounds. Here, we demonstrate the feasibility of a more comprehensive approach using high-throughput screening to identify inhibitors of a gain-of-function mutation in the SCN8A gene associated with severe pediatric epilepsy. METHODS:We developed cellular models expressing wild-type or an R1872Q mutation in the Nav 1.6 sodium channel encoded by SCN8A. Voltage clamp experiments in HEK-293 cells expressing the SCN8A R1872Q mutation demonstrated a leftward shift in sodium channel activation as well as delayed inactivation; both changes are consistent with a gain-of-function mutation. We next developed a fluorescence-based, sodium flux assay and used it to assess an extensive library of approved drugs, including a panel of antiepileptic drugs, for inhibitory activity in the mutated cell line. Lead candidates were evaluated in follow-on studies to generate concentration-response curves for inhibiting sodium influx. Select compounds of clinical interest were evaluated by electrophysiology to further characterize drug effects on wild-type and mutant sodium channel functions. RESULTS:The screen identified 90 drugs that significantly inhibited sodium influx in the R1872Q cell line. Four drugs of potential clinical interest-amitriptyline, carvedilol, nilvadipine, and carbamazepine-were further investigated and demonstrated concentration-dependent inhibition of sodium channel currents. SIGNIFICANCE:A comprehensive drug repurposing screen identified potential new candidates for the treatment of epilepsy caused by the R1872Q mutation in the SCN8A gene.

Full Text

Cited Authors

  • Atkin, TA; Maher, CM; Gerlach, AC; Gay, BC; Antonio, BM; Santos, SC; Padilla, KM; Rader, J; Krafte, DS; Fox, MA; Stewart, GR; Petrovski, S; Devinsky, O; Might, M; Petrou, S; Goldstein, DB

Published Date

  • April 2018

Published In

Volume / Issue

  • 59 / 4

Start / End Page

  • 802 - 813

PubMed ID

  • 29574705

Pubmed Central ID

  • 29574705

Electronic International Standard Serial Number (EISSN)

  • 1528-1167

International Standard Serial Number (ISSN)

  • 0013-9580

Digital Object Identifier (DOI)

  • 10.1111/epi.14037

Language

  • eng